AVI BioPharma names chief executive

Chris Garabedian joins US biopharmaceutical firm from Celgene

Chris Garabedian will become chief executive and president of AVI BioPharma on 1 January 2011.

Garabedian, who has been a director of the Bothell, Washington-based biopharmaceutical firm since June, will continue as a member of the board. David Boyle, who held the post of interim ceo and president, will continue in his role as chief financial officer and senior vice president.

Garabedian brings to AVI broad biotechnology and pharmaceutical experience. He has been vice president of corporate strategy at Celgene since July 2007. Before this, he held several key roles at Gilead Sciences between 1997 and 2005, including vice president of corporate development, vice president of marketing and vice president of medical affairs.

He also held various commercial and product development roles at COR Therapeutics and Abbott Laboratories and began his career as a consultant to the pharmaceutical industry.

‘We believe Chris' experience is ideal for driving products from early development through commercialisation, while also leveraging business development opportunities to unlock further value from our RNA-based therapeutics technology platforms,’ said William Goolsbee, AVI's chairman.

You may also like

Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
Finance

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia
Analysis

From West to East: building biotech bridges across APAC and the Middle East

Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
Distribution

Er-Kim partners with Sentynl Therapeutics to expand access to ultra-rare disease treatments Nulibry and Zokinvy

The collaboration aims to provide timely access to these EMA- and FDA-approved therapies for patients with life-threatening ultra-rare conditions, including molybdenum cofactor deficiency Type A and Hutchinson-Gilford Progeria Syndrome
Manufacturing

Gerresheimer and Portal Instruments team up to commercialise PRIME Nexus reusable autoinjector

Gerresheimer and Portal Instruments are joining forces to develop and manufacture the PRIME Nexus syringe-based, reusable, connected autoinjector platform, offering pharmaceutical companies an end-to-end solution for delivering chronic disease therapies
Subscribe now